Cargando…
Pyrazole-Based Thrombin Inhibitors with a Serine-Trapping Mechanism of Action: Synthesis and Biological Activity
New antithrombotic drugs are needed to combat thrombosis, a dangerous pathology that causes myocardial infarction and ischemic stroke. In this respect, thrombin (FIIa) represents an important drug target. We herein report the synthesis and biological activity of a series of 1H-pyrazol-5-amine-based...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696832/ https://www.ncbi.nlm.nih.gov/pubmed/36355511 http://dx.doi.org/10.3390/ph15111340 |
_version_ | 1784838406139805696 |
---|---|
author | Dunker, Calvin Imberg, Lukas Siutkina, Alena I. Erbacher, Catharina Daniliuc, Constantin G. Karst, Uwe Kalinin, Dmitrii V. |
author_facet | Dunker, Calvin Imberg, Lukas Siutkina, Alena I. Erbacher, Catharina Daniliuc, Constantin G. Karst, Uwe Kalinin, Dmitrii V. |
author_sort | Dunker, Calvin |
collection | PubMed |
description | New antithrombotic drugs are needed to combat thrombosis, a dangerous pathology that causes myocardial infarction and ischemic stroke. In this respect, thrombin (FIIa) represents an important drug target. We herein report the synthesis and biological activity of a series of 1H-pyrazol-5-amine-based thrombin inhibitors with a serine-trapping mechanism of action. Among synthesized compounds, flexible acylated 1H-pyrazol-5-amines 24e, 34a, and 34b were identified as potent 16–80 nM thrombin inhibitors, which showed practically no off-targeting effect against other physiologically relevant serine proteases. To prove that synthesized compounds are covalent thrombin inhibitors, the most potent derivative 24e (FIIa IC(50) = 16 nM) was studied in a mass-shift assay, where it has been shown that 24e transfers its acyl moiety (pivaloyl) to the catalytic Ser195 of thrombin. Performed herein docking studies also confirmed the covalent mechanism of thrombin inhibition by synthesized compounds. Acylated aminopyrazoles found during this study showed only limited effects on plasma coagulation in activated partial thrombin time (aPTT) and prothrombin time (PT) in vitro assays. However, such thrombin inhibitors are expected to have virtually no effect on bleeding time and can be used as a starting point for developing a safer alternative to traditional non-covalent anticoagulants. |
format | Online Article Text |
id | pubmed-9696832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96968322022-11-26 Pyrazole-Based Thrombin Inhibitors with a Serine-Trapping Mechanism of Action: Synthesis and Biological Activity Dunker, Calvin Imberg, Lukas Siutkina, Alena I. Erbacher, Catharina Daniliuc, Constantin G. Karst, Uwe Kalinin, Dmitrii V. Pharmaceuticals (Basel) Article New antithrombotic drugs are needed to combat thrombosis, a dangerous pathology that causes myocardial infarction and ischemic stroke. In this respect, thrombin (FIIa) represents an important drug target. We herein report the synthesis and biological activity of a series of 1H-pyrazol-5-amine-based thrombin inhibitors with a serine-trapping mechanism of action. Among synthesized compounds, flexible acylated 1H-pyrazol-5-amines 24e, 34a, and 34b were identified as potent 16–80 nM thrombin inhibitors, which showed practically no off-targeting effect against other physiologically relevant serine proteases. To prove that synthesized compounds are covalent thrombin inhibitors, the most potent derivative 24e (FIIa IC(50) = 16 nM) was studied in a mass-shift assay, where it has been shown that 24e transfers its acyl moiety (pivaloyl) to the catalytic Ser195 of thrombin. Performed herein docking studies also confirmed the covalent mechanism of thrombin inhibition by synthesized compounds. Acylated aminopyrazoles found during this study showed only limited effects on plasma coagulation in activated partial thrombin time (aPTT) and prothrombin time (PT) in vitro assays. However, such thrombin inhibitors are expected to have virtually no effect on bleeding time and can be used as a starting point for developing a safer alternative to traditional non-covalent anticoagulants. MDPI 2022-10-28 /pmc/articles/PMC9696832/ /pubmed/36355511 http://dx.doi.org/10.3390/ph15111340 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Dunker, Calvin Imberg, Lukas Siutkina, Alena I. Erbacher, Catharina Daniliuc, Constantin G. Karst, Uwe Kalinin, Dmitrii V. Pyrazole-Based Thrombin Inhibitors with a Serine-Trapping Mechanism of Action: Synthesis and Biological Activity |
title | Pyrazole-Based Thrombin Inhibitors with a Serine-Trapping Mechanism of Action: Synthesis and Biological Activity |
title_full | Pyrazole-Based Thrombin Inhibitors with a Serine-Trapping Mechanism of Action: Synthesis and Biological Activity |
title_fullStr | Pyrazole-Based Thrombin Inhibitors with a Serine-Trapping Mechanism of Action: Synthesis and Biological Activity |
title_full_unstemmed | Pyrazole-Based Thrombin Inhibitors with a Serine-Trapping Mechanism of Action: Synthesis and Biological Activity |
title_short | Pyrazole-Based Thrombin Inhibitors with a Serine-Trapping Mechanism of Action: Synthesis and Biological Activity |
title_sort | pyrazole-based thrombin inhibitors with a serine-trapping mechanism of action: synthesis and biological activity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696832/ https://www.ncbi.nlm.nih.gov/pubmed/36355511 http://dx.doi.org/10.3390/ph15111340 |
work_keys_str_mv | AT dunkercalvin pyrazolebasedthrombininhibitorswithaserinetrappingmechanismofactionsynthesisandbiologicalactivity AT imberglukas pyrazolebasedthrombininhibitorswithaserinetrappingmechanismofactionsynthesisandbiologicalactivity AT siutkinaalenai pyrazolebasedthrombininhibitorswithaserinetrappingmechanismofactionsynthesisandbiologicalactivity AT erbachercatharina pyrazolebasedthrombininhibitorswithaserinetrappingmechanismofactionsynthesisandbiologicalactivity AT daniliucconstanting pyrazolebasedthrombininhibitorswithaserinetrappingmechanismofactionsynthesisandbiologicalactivity AT karstuwe pyrazolebasedthrombininhibitorswithaserinetrappingmechanismofactionsynthesisandbiologicalactivity AT kalinindmitriiv pyrazolebasedthrombininhibitorswithaserinetrappingmechanismofactionsynthesisandbiologicalactivity |